Quizartinib (AC220)

Name: Quizartinib (AC220)
Brand: Selleck Chemicals
SKU: S1526
Rating: 5 (84 reviews)

For research use only.

Catalog No.S1526

84 publications

CAS No. 950769-58-1

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Quizartinib (AC220) induces apoptosis of tumor cells. Phase 3.

Selleck's Quizartinib (AC220) has been cited by 84 publications

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Nat Med, 2017, 23(1):69-78

PubMed: 27941792 ( click the link to review the publication )

Autophagy, 2021, 1-10

PubMed: 33446043 ( click the link to review the publication )

Blood Cancer J, 2021, 11(3):57

PubMed: 33714981 ( click the link to review the publication )

Cancer Discov, 2021, candisc.0738.2020

PubMed: 33436370 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):676-690

PubMed: 33568357 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):397

PubMed: 33777220 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13849

PubMed: 33566442 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Haematologica, 2020, 15 pii: haematol 2019 244020

PubMed: 32414851 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

Eur J Med Chem, 2020, 193:112232

PubMed: 32199135 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(3):2308-2318

PubMed: 31881122 ( click the link to review the publication )

J Cell Mol Med, 2020, 25

PubMed: 32450611 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16187

PubMed: 32999332 ( click the link to review the publication )

Sci Rep, 2020, 10(1):1906

PubMed: 32024878 ( click the link to review the publication )

Transl Oncol, 2020, 1;13(4):100766

PubMed: 32247263 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Pharmacol Res, 2020, 151:104556

PubMed: 31778791 ( click the link to review the publication )

FEBS Open Bio, 2020, 10.1002/2211-5463.12827

PubMed: 32128992 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Sci Transl Med, 2019,

PubMed: 31484791 ( click the link to review the publication )

Autophagy, 2019, 15(9):1558-1571

PubMed: 30821613 ( click the link to review the publication )
Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Theriogenology, 2019, 126:145-152

PubMed: 30553232 ( click the link to review the publication )

Cell Rep, 2019, 26(11):2916-2928.e13

PubMed: 30865883 ( click the link to review the publication )

FEBS Lett, 2019, 593(16):2162-2176

PubMed: 31135968 ( click the link to review the publication )

Hemasphere, 2019, 3(2):e182

PubMed: 31723821 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6111-6123

PubMed: 31692922 ( click the link to review the publication )

Blood, 2018, 25;131(4):426-438

PubMed: 29187377 ( click the link to review the publication )

Blood, 2018, 132(1):67-77.

PubMed: 29784639 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Haematologica, 2018, haematol.2018.189399

PubMed: 29748445 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

Oncogene, 2018, 37(6):787-797

PubMed: 29059168 ( click the link to review the publication )

mBio, 2018, 9(2)e00682-18

PubMed: 29691342 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):138

PubMed: 29374185 ( click the link to review the publication )

Neoplasia, 2018, 20(1):1-11

PubMed: 29172076 ( click the link to review the publication )

Nephrol Dial Transplant, 2018, 10.1093/ndt/gfy385

PubMed: 30590794 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0196805

PubMed: 29723246 ( click the link to review the publication )

Exp Hematol, 2018, 58:52-58

PubMed: 28947392 ( click the link to review the publication )

J Ophthalmol, 2018, 2018:2518568

PubMed: 29854425 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Leukemia, 2018, 32(11):2374-2387

PubMed: 29743719 ( click the link to review the publication )
Oncotarget, 2018, 9(24):16917-16931

PubMed: 29682194 ( click the link to review the publication )

Blood, 2017, 130(1):48-58

PubMed: 28490572 ( click the link to review the publication )

Leukemia, 2017, 31(11):2336-2346

PubMed: 28280274 ( click the link to review the publication )

Cancer Res, 2017, 77(7):1697-1708

PubMed: 28108507 ( click the link to review the publication )

Leuk Lymphoma, 2017, 10.1080/10428194.2017.1289522

PubMed: 28276286 ( click the link to review the publication )

Blood Adv, 2017, 1(20):1635-1644

PubMed: 29296810 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52026-52044

PubMed: 28881711 ( click the link to review the publication )

Blood, 2016, 127(23):2890-902

PubMed: 27099147 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1528-37

PubMed: 26822154 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1214-24

PubMed: 26833125 ( click the link to review the publication )

Sci Rep, 2016, 6:28032

PubMed: 27346558 ( click the link to review the publication )

Ann Hematol, 2016, 95(5):783-91

PubMed: 26891877 ( click the link to review the publication )

PLoS One, 2016, 11(7):e0158290

PubMed: 27387666 ( click the link to review the publication )

Int J Hematol, 2016, 103(1):95-106

PubMed: 26590920 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49786-49799

PubMed: 27391351 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Leukemia, 2015, 29(12):2382-9

PubMed: 26172401 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38061-78

PubMed: 26515730 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Blood, 2014, 123(18):2826-37

PubMed: 24668492 ( click the link to review the publication )

Blood, 2014, 123(5):734-42

PubMed: 24282218 ( click the link to review the publication )

Nat Commun, 2014, 5:3672

PubMed: 24739485 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Leukemia, 2014, 28(2):293-301

PubMed: 23748345 ( click the link to review the publication )

Genes Dev, 2014, 28(11):1179-90

PubMed: 24888589 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1320661111

PubMed: 24623852 ( click the link to review the publication )

Cancer Discov, 2014, 4(2):200-15

PubMed: 24362263 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

J Biol Chem, 2014, 289(45):31053-65

PubMed: 25237195 ( click the link to review the publication )

PLoS One, 2013, 8(8): e71266

PubMed: 23967177 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74653

PubMed: 24040307 ( click the link to review the publication )

Leuk Res, 2013, 37(11):1557-64

PubMed: 23998902 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(3):858-76

PubMed: 22250956 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

The most potent cellular FLT3-ITD inhibitor.

Targets

FLT3 (ITD) ^[1] (MV4-11 cells)	FLT3 (WT) ^[1] (RS4;11 cells)
1.1 nM	4.2 nM

In vitro

AC220, a unique, potent and selective inhibitor of FLT3, has high affinity for FLT3 with a K_d value of 1.6 nM. AC220 inhibits the autophosphorylation of FLT3 in the human leukemia cell lines MV4-11 which harbor a homozygous FLT3-ITD mutation and is FLT3 dependent, and RS4;11 which expresses wild-type FLT3 with IC50 values of 1.1 nM and 4.2 nM, respectively. AC220 is the most potent cellular FLT3-ITD inhibitor, leading to the most significant inhibition of MV4-11 cell proliferation with IC50 of 0.56 nM compared to all other FLT3 inhibitors whose IC50 values range from 0.87 nM to 64 nM. AC220 has no inhibitory activity against the proliferation of A375 cells which harbor an activating mutation in BRAF and are not FLT3 dependent, indicating a large window between FLT3 inhibition and general cytotoxic effects. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL60/VCR	NX;hZWhTTnWwY4Tpc44hSXO\|YYm=	Mlz3NE4yNTFyIN88US=>	NEG5dZI{OCCvaX6=	NV\ZVWlx\W6qYX7j[ZMhfXC2YXvlJI9nKHO3YoP0doF1\XNib3[gRWJETzJiYX7kJGFDS0JzIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4N{G3O{c,OjN7NkexO\|c9N2F-
K562/ABCB1	MWXGeY5kfGmxbjDBd5NigQ>?	NHPDPVIxNjFvMUCg{txO	MYGzNEBucW5?	M3fMdoVvcGGwY3XzJJVxfGGtZTDv[kB{fWK\|dILheIV{KG:oIFHCR2czKGGwZDDBRmNDOSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
8226/MR20	MXvGeY5kfGmxbjDBd5NigQ>?	MXewMlEuOTBizszN	NEnQO4w{OCCvaX6=	NELzdIdmdmijbnPld{B2eHSja3Wgc4Yhe3Wkc4TyZZRmeyCxZjDBRmNIOiCjbnSgRWJESjFiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	NV:xbWg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
K562/ABCG2	MX3GeY5kfGmxbjDBd5NigQ>?	M3nQPFAvOS1zMDFOwG0>	NGjFTVE{OCCvaX6=	NYTUfmZC\W6qYX7j[ZMhfXC2YXvlJI9nKHO3YoP0doF1\XNib3[gRWJETzJiYX7kJGFDS0JzIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	NXv6elJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
MCF-7 FLV1000	M3vDc2tqdmG\|ZTDBd5NigQ>?	NUXrflNTOOLCk{OwJOK2VQ>?	MV:1JI1qdg>?	Mlj1[IVkemWjc3XzJHsyOjWLXT3JRWFRKHCqb4TvcIFj\Wyrbnegc4YhSUKFQkGgZZQhUUN3MDDv[kA{NjNizszN	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
MCF-7 FLV1000	NVzWXoR{U2mwYYPlJGF{e2G7	MV6w5qCUOzBiwsXN	MlXLOUBucW5?	NV3USFA3\GWlcnXhd4V{KFtzMkXJYU1KSUGSIIDoc5RwdGGkZXzpcochd2ZiQVLDRlIh[XRiSVO1NEBw\iByLkC3JO69VQ>?	NWLvOnRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
K562/ABCG2	MnvCR4VtdCCYaXHibYxqfHliQYPzZZl{	MV[wMlEwOC53L{GgxtVO	NHjGOGw6PiCq	MVrz[Y5{cXSrenXzJGs2PjJxQVLDS\|Ih[2WubIOgeI8hdWm2b4jhcpRzd26nIITvdI91\WOjbtMg	NUC4XJNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
8226/MR20	NFGzNnNE\WyuIG\pZYJqdGm2eTDBd5NigXN?	NXfaUpJ[OC5zINM1US=>	MUC5OkBp	MoLJd4Vve2m2aYrld{BMPTZ{L1HCR2czKGOnbHzzJJRwKG2rdH;4ZY51em:wZTD0c5BwfGWlYX9CpC=>	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
HMC1.1	NE\2bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkPmTWM2OD1zNDDuUS=>	NXXCR5JoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
HMC1.2	NFvTfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2mycWlEPTB;MUeyO{BvVQ>?	NHKy[XA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
p815	NE\DUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MojKTWM2OD12NEWgcm0>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Kasumi-1	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX25PI5lUUN3ME2zOkBvVQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
M-07e + SCF	NFq2OHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{XjXWlEPTB;N{egcm0>	Mn3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
EOL-1	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkLETWM2OD1zIH7N	Mk\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
MV4;11	M1v5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFrKVWNKSzVyPDCxJI5O	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MOLM14	NIm4dolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml[yTWM2ODxiMTDuUS=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.221	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV3JR\|UxRTZ5NTDuUS=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.279	M3TiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVjJR\|UxRTN2M{Sgcm0>	NELlS\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.299	M2ey[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUnSR\|NJUUN3ME23NlQ5KG6P	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.305	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlv1TWM2OD15MEe5JI5O	Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.375	NWDMSHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkLSTWM2OD13MEOgcm0>	M4PDeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Pat.379	M1;zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mk\RTWM2OD16ME[gcm0>	MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.368	NGnHXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGC0bWVKSzVyPUK3NFAhdk1?	MnP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.601	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkLsTWM2OD1zMUWzJI5O	M3;pNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
HMC1.1	Mn7nRZBweHSxc3nzJGF{e2G7			MV7JR\|UxRTNzIH7N	NWT1U\|lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
p815	M4\NbmFxd3C2b4Ppd{BCe3OjeR?=			MmfzTWM2OD1\|NEGgcm0>	M{jDNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Kasumi-1	Mlj0RZBweHSxc3nzJGF{e2G7			Mnv1TWM2OD14NzDuUS=>	NFTDbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
M-07e + SCF	NXnuNpFLSXCxcITvd4l{KEG\|c3H5			NHTXSlZKSzVyPUe4JI5O	M33MW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
EOL-1	NYTaUGpZSXCxcITvd4l{KEG\|c3H5			M3;tUmlEPTB:IEGgcm0>	M{\MdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
MV4;11	M3rBTWFxd3C2b4Ppd{BCe3OjeR?=			NGPieZBKSzVyPUKgcm0>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MOLM14	NVLabY16SXCxcITvd4l{KEG\|c3H5			MX7JR\|UxRTNibl2=	NU\jTIoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
GIST822	M3\1WWFxd3C2b4Ppd{BCe3OjeR?=			MnT2TWM2OD1zMEmgcm0>	M2TGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Pat.368	NW\POWszSXCxcITvd4l{KEG\|c3H5			NWD4OlZYUUN3ME2yPVk5KG6P	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.601	NFvG[FVCeG:ydH;zbZMhSXO\|YYm=			M{fqNWlEPTB;OEe2JI5O	M3S4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
MV4-11	NEXS[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33l[FczKGh?	M2PQNGlEPTB;MD6zJI5O	NVrPTlRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVI6OzFpPkKzOFEzQTNzPD;hQi=>
MOLM-14	NEjm[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWizN5NCPzJiaB?=	MWHJR\|UxRTBwMTDuUS=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
SEM-K2	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWO3NkBp	NY\oNGFMUUN3ME2wMlQhdk1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
RS4;11	NWO2[4puT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XKT\|czKGh?	NHf1NFZKSzVyPkGwMFAxOCCwTR?=	MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
THP-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIT0[204OiCq	NVfh[XJ7UUN3ME6xNEwxODBibl2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
MV4-11	Mn3GRZBweHSxc3nzJGF{e2G7		MW[4M\|I1KGh?	M2rCRolv\HWlZYOgd4lodmmoaXPhcpQh[W6mIHTvd4Uu\GWyZX7k[Y51KFCDUmCgZ4xm[X[jZ3WgZY5lKGGlY4XteYxifGmxbjDv[kB{fWJvMl6gSG5C	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
MOLM-14	M2[2WGFxd3C2b4Ppd{BCe3OjeR?=		MlLzPE8zPCCq	M4OyOIlv\HWlZYOgd4lodmmoaXPhcpQh[W6mIHTvd4Uu\GWyZX7k[Y51KFCDUmCgZ4xm[X[jZ3WgZY5lKGGlY4XteYxifGmxbjDv[kB{fWJvMl6gSG5C	Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
SEM-K2	MlniRZBweHSxc3nzJGF{e2G7		M3[2N\|gwOjRiaB?=	MXvpcoR2[2W\|IIPp[45q\mmlYX70JIFv\CCmb4PlMYRmeGWwZHXueEBRSVKSIHPs[YF3[WenIHHu[EBi[2O3bYXsZZRqd25ib3[gd5VjNTKQIFTORS=>	M3Hlc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
AML	NF3PZ4dEgXSxdH;4bYNqfHliYYPzZZk>			M2fjRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGFOVCClZXzsd{Bqe2:uYYTl[EBnem:vIILlcIFxe2WmIHHjeZRmKG27ZXzvbYQhdGW3a3XtbYEheGG2aXXueEBp[XKkb4LpcochTkyWMzDJWGQhdXW2YYTpc44h[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFA{KM7:TT6=	Mlm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
MV4-11	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		NGHyWow4OiCqcoO=	NIHRZ2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IECuNFAxPTZizszNMi=>	MkHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
blast cells	MkfjSpVv[3Srb36gZZN{[Xl?		NUHIZYJpOiCqcoO=	MonoTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCkbHHzeEBk\WyuczDh[pRmeiB{IHjyd{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XuZ4UtKEmFNUCgQUAxNjByMEig{txONg>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
RS4-11	MmHiSpVv[3Srb36gZZN{[Xl?		NFuxW2IzKGi{cx?=	MX7Jcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFKVND2xNUBk\WyuczDh[pRmeiB{IHjyd{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAxOTFizszNMi=>	MojwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
AML	NWiw[o5zTnWwY4Tpc44h[XO\|YYm=			MmH3TY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSU2OIHPlcIx{KGm\|b3zheIVlKG[{b32gdoVt[XC\|ZXSgZYN2fGVibYnlcI9q\CCuZYXr[Y1q[SCyYYTp[Y51KGK7IGfld5Rmem5iYnzveJRqdmduIFnDOVAhRSByLkCwNkDPxE1w	NFO1clM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[1OFQxQCd-MUm2OVQ1ODh:L3G+
RS4-11	Ml7QSpVv[3Srb36gZZN{[Xl?		MkTBNkBpenN?	M3LFcmlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFKVND2xNUBk\WyuczDh[pRmeiB{IHjyd{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAxPDJizszNMi=>	M1nuTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkW0OFA5Lz5zOU[1OFQxQDxxYU6=
MV4-11	M4XRWGFvfGm2dX3vdkBie3OjeR?=	MWixNEBu\y:tZx?=	Mlr4OlAh\GG7cx?=	NY\RXpd[SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JicnXndo94fGhiYYSgZZQhOTBibXevb4ctKHCxIE[wJIRigXNicH;zeEB1emWjdH3lcpQ>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
MV4-11	MX\BcpRqfHWvb4KgZZN{[Xl?	M4n3blEhdWdxa3ev[IF6	MmjHN\|Ah\GG7cx?=	MWTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhdW:3c3WgZo9v\SCvYYLyc5ch\W6pcnHmeI1mdnRibX;k[Ywh[XO\|ZYPz[YQh[XNiaX7jdoVie2VibX;1d4UhdGmoZTDzdIFvKGG2IEGgcYcwc2dxZHH5MEBxdyCob4KgN\|Ah\GG7czDt[YF{fXKnZDDvckBl[XliN{egdI9{fCCmb4Pl	NX7oZ3ZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	NWD6THR2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2\Kc\|czKGi{cx?=	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wNFA2PiEQvF2u	MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
HEK293	NHvDSW9HfW6ldHnvckBie3OjeR?=			MmHLRolv\GmwZzDh[oZqdmm2eTD0c{BHVFR\|IHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDjc41x\XSrdHn2[UBjcW6maX7nJIF{e2G7LDDL[EA:KDBwMECxOkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	NWf5d5hpSW62aYT1cY9zKGG\|c3H5	NFn1Z3YyKG2pL3vn	NX\FfYNTOjhiZHH5dy=>	M1\Wb2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDheIh6dWmlIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiCpcn;3eIgh[XRiMTDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiZIXybY5oKGSxc3nu[{Bx\XKrb3S=	NYPhRVRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	M4HuSmFvfGm2dX3vdkBie3OjeR?=	Mk\GN{Bu\y:tZx?=	MYeyPEBl[Xm\|	M3KwZmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDheIh6dWmlIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIILl[5Jme3Orb36gZZQhOyCvZz;r[{wheG9iUVSg[o9zKDJ6IHThfZMhdWWjc4Xy[YQh[W[2ZYKg[I9{cW6pIIDldolw\A>?	NUjoPZpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	M1H1eWFvfGm2dX3vdkBie3OjeR?=	NYfBcJc2OTBibXevb4c>	MkP4Nlgh\GG7cx?=	MkTkRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhicnXndoV{e2mxbjDheEAyOCCvZz;r[{wheG9iUVSg[o9zKDJ6IHThfZMhdWWjc4Xy[YQh[W[2ZYKg[I9{cW6pIIDldolw\A>?	NXjrfY5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	NY\6RZRESW62aYT1cY9zKGG\|c3H5	NH:wbI4{KG2pL3vn	NFjpd2IzQCCmYYnz	MnfMRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjD0eY1weiC4b3z1cYUh[XRiMzDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIh\G:\|aX7nJJBmemmxZB?=	NUG2SVc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	MnzBRY51cXS3bX;yJIF{e2G7	M2rpblExKG2pL3vn	MoDRNlgh\GG7cx?=	MmrQRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjD0eY1weiC4b3z1cYUh[XRiMUCgcYcwc2duIIDvJHFFKG[xcjCyPEBl[Xm\|IH3lZZN2emWmIHHmeIVzKGSxc3nu[{Bx\XKrb3S=	NFXzfmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
MV4-11	MlXpRY51cXS3bX;yJIF{e2G7	MoLKNVAhdWdxa3e=	MmfGNlgh\GG7cx?=	Mnf6RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGe{b4f0bEBifCBzMDDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIhOzJiZHH5d{Bxd3O2ZH;z[S=>	MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MOLM13	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NIHPVZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{BmgHC{ZYPzbY5oKE[OVEOtTXRFKG23dHHueEwhT0l3MDC9JFAvODB2IN88UU4>	NUDBO45YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlY6OzFpPkKyO\|I3QTNzPD;hQi=>
MV411	NHvLVpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4XMN\|Q5KGi{cx?=	MoXtS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1OTFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFMvOzFizszNMi=>	NVHnemxKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
THP1	NFXSSJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MonhOFghcHK\|	NVX4ZWRnT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXEiSMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhYFSWIHHzd4F6NCCJSUWwJF0hPS53N{Sg{txONg>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOEC3PUc,OjVzMEiwO\|k9N2F-
HL60	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2XuOFQ5KGi{cx?=	M1LNRmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFgvODF2IN88UU4>	NXu2bZFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
32D	Moj1SpVv[3Srb36gZZN{[Xl?		Ml\ZO\|IhcHK\|	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGZNXDNiSWTEJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgN\|JFKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFAxODFizszNMi=>	MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MV4-11	NGfYdnpHfW6ldHnvckBie3OjeR?=		MmrBO\|IhcHK\|	NXjxV3g3UW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDoc41wgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4xODNizszNMi=>	MoK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MOLM-13	MkG0SpVv[3Srb36gZZN{[Xl?		NIrzco84OiCqcoO=	M4nIdGlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaHX0[ZJwgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNU2xONTF\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvODB2IN88UU4>	M2j6TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
32D	M1fYZ2Z2dmO2aX;uJIF{e2G7		NVH0VWpjPzJiaILz	NX\3ZYJbUW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBFQDN3WTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkCxOkDPxE1w	NX3lVpBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
32D	MkXhSpVv[3Srb36gZZN{[Xl?		NGjCcGg4OiCqcoO=	M13ZWmlvcGmkaYTpc44hd2ZiZIL1[{Bz\XOrc4ThcpQhcHWvYX6gSmxVOyCLVFSgSFg{PVZibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SB\|MlSgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOC5yMkeg{txONg>?	M33XNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
Sf9	NX;nVJhqTnWwY4Tpc44h[XO\|YYm=		M{THc\|QhcHK\|	MULJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCJU2SteIFo\2WmIF\MWFMhc2mwYYPlJIRwdWGrbjCoXVU3PyC2bzDTPVk{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJJV{cW6pIFjldlIheGWydHnk[UBieyC\|dXLzeJJifGViYX\0[ZIhPCCqcoOgZpkhU2mwYYPlMWdtdyCjc4PhfUwhUUN3MDC9JFAvODZ7IN88UU4>	NGTCNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
32D	M3;oR2Z2dmO2aX;uJIF{e2G7		M1XxSFczKGi{cx?=	NVv1doJ4UW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBFQDN3RjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkG1JO69VS5?	NFH1d2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
32D	NHjMVoVHfW6ldHnvckBie3OjeR?=		NVLGV4lrPzJiaILz	NVvMe2ZNUW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBHPjlzTDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkKyJO69VS5?	M{\sZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
Sf9	MkfGSpVv[3Srb36gZZN{[Xl?		NX3t[XVrOTJyIH3pcpM>	NVzMOFdnUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBIW1RvdHHn[4VlKF[HR1\SNkBscW6jc3Wg[I9u[WmwIDjWO\|g6KHSxIG[xN\|U3MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDpcpNm[3RiU3[5JINmdGy\|IIXzbY5oKHCxbInHcJU1QlS7cjDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBi\nSncjCxNlAhdWmwczDifUBMcW6jc3WtS4xwKGG\|c3H5MEBKSzVyIE2gNE41OyEQvF2u	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
RS4:11	NV;F[JNmTnWwY4Tpc44h[XO\|YYm=		M3;TV\|czKGi{cx?=	MW\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCqb33vfplod3W\|IF\MWFMhcW5iaIXtZY4hWlN2OkGxJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDJwMjFOwG0v	NXvse3U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
MV4-11	NXHpXnUxSW62aYT1cY9zKGG\|c3H5	MonSNVAhdWdxa3e=	MlKxOFgh\GG7cx?=	NXPGd4ZySW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5IhemWpcnXzd4lwdiCjdDCxNEBu\y:tZzygdI8heWRiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDVibXXhd5Vz\WRiZIXybY5oKDR6IHThfZMheG:\|dDDsZZN1KGSxc3W=	NID4[Ys9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	MV3BcpRqfHWvb4KgZZN{[Xl?	MXmxNEBu\y:tZx?=	MmDWOFgh\GG7cx?=	MVrBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDy[Ydz\XO\|aX;uJIF1KDFyIH3nM4toNCCybzDx[EBi\G2rbnnzeIVz\WRib36g[IF6KDhidH:gNVIhdWWjc4Xy[YQh\HW{aX7nJFQ5KGSjeYOgdI9{fCCuYYP0JIRwe2V?	NF72V2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		NWjpUVRSPzJiaILz	Ml\zR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODByNkig{txONg>?	M{n4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUSyN\|E4Lz5{NkG0NlMyPzxxYU6=
Sf21	NWjmNWtYTnWwY4Tpc44h[XO\|YYm=		M{fUcVE2KG2rboO=	NFHFR4JKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF\MWFMh\XiycnXzd4VlKGmwIHnud4VkfCCVZkKxJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDwc4x6MEeudUrUfZIqKHO3YoP0doF1\SCjZHTpeIlwdiCob4KgN\|AhdWmwczDpckBxemW\|ZX7j[UBw\iCdZ3HtcYEuOzKSXVHUVEBjgSCWUj3GVmVVKGG\|c3H5MEBKSzVyIE2gNE4xOjZyODFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6N{i2NEc,OjdzOEe4OlA9N2F-
MV4-11	Mmi4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIH0e\|U1QCCqcoO=	NWH6eoRsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ2LUGxJINmdGy\|IHX4dJJme3OrbnegSmxVOy2LVFSgZYZ1\XJiNEigbJJ{KGK7IGjUWEBie3OjeTygS2k2OCB;IEGuNVA{KM7:TT6=	NEHvRnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4O\|g3OCd-MkexPFc5PjB:L3G+
HL60	NWj3SHpET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NW\rOXd1PDhiaILz	M4Pwc2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhNPjBiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRlzUMVMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFEvPDh6IN88UU4>	NVH0dXFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
THP1	M4Lo[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnvlOFghcHK\|	NETKPVdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBVUFBzIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIF\MWE0{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUAzNjF{NTFOwG0v	NW[yTpFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
K562	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoXtOFghcHK\|	MknKS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT\|U3OiClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gNk43OzhizszNMi=>	NWfCWHY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
Sf21	MoDFSpVv[3Srb36gZZN{[Xl?		MlPCNVAhdWmwcx?=	MlXBTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSgdoVkd22kaX7hcpQhcHWvYX6ge4lt\C22eYDlJGZNXDNiKEW2OEB1dyCnbnSgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lIyKGOnbHzzJJV{cW6pIFHicJRq\GViYYOgd5Vje3S{YYTlJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[TN\|UG3BWHAh[W[2ZYKgNVAhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMEK1OUDPxE1w	NVvmTGtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
Sf21	NU\pcZJvTnWwY4Tpc44h[XO\|YYm=		NUX3XXA2OTBibXnudy=>	MWLJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUMZRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjD3bYxlNXS7cHWgSmxVOyBqNU[0JJRwKGWwZDDy[ZNq\HWnczmgSFg{PVlibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jJzIHPlcIx{KHW\|aX7nJGFjdHSrZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNlM2PSEQvF2u	NFjqblU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC0N\|c6PCd-MkiwOFM4QTR:L3G+
MV4-11	NImzUWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1\jSGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCqYYLic5JqdmdiRlzUN{1KXERibYX0ZY51KGK7IGjUWEBie3OjeTygS2k2OCB;IEGuNVA{KM7:TT6=	NHz6XW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC0N\|c6PCd-MkiwOFM4QTR:L3G+
THP1	M1vuemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MlPRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWGhROSClZXzsd{Bp[XKkb4Lpcochf2muZD30fZBmKE[OVEOgZpkhYFSWIHHzd4F6NCCJSUWwJF0hOi5zMkWg{txONg>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB2M{e5OEc,OjhyNEO3PVQ9N2F-
BAF3	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnHiO\|IhcHK\|	NVjhW5lGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVnUSE1FQDN3RzDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFAxOyEQvF2u	MnLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NHjxXmVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWK3NkBpenN?	MlvTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2SSCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	NEDNXGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	M{\KbWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVq1VFI5PzJiaILz	NYTTVWN{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVS4N\|VJKG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMECzJO69VS5?	Mo\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MOLM13	M4fBWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkLPO\|IhcHK\|	NEfUUJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMz3JWGQhdXW2YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NX3hS4JXPzJiaILz	NH[wb3ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOg[ZhxemW\|c3nu[{BVTUxvZoXz[YQhTkyWMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCwNFMh\|ryPLh?=	Ml7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NG\PcJZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGj0V3I4OiCqcoO=	M4nqbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PU5ibYX0ZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCwNFMh\|ryPLh?=	NVvsOGZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM14	NUPqU5oySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1zae\|czKGi{cx?=	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xOEBk\WyuczDoZZJjd3KrbnegSmxVOy2LVFSgcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	NEfNXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	NH3UWmRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NInXW2w4OiCqcoO=	MorRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRDDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFAxOyEQvF2u	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
MV4-11	NVPzVnJnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXKyVo15PzJiaILz	NGLaXo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	MojXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGLUTGg4OiCqcoO=	NX:2bGJlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhWESJRmLhcJBp[S22cnHud4Zwem2nZDDtc5V{\SCEQV[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNFA{KM7:TT6=	NYizd49YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWnLcHNpPzJiaILz	MlrSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUR6M{XZJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODJizszNMi=>	M2C1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVy3NkBpenN?	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDQSGdHWmKndHGteJJidnOob4Lt[YQhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODB2NDFOwG0v	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NEW1WldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1nLc\|czKGi{cx?=	M1KxPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2GOEO1WkBufXSjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODFzIN88UU4>	MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	MoTHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVm3NkBpenN?	MkTLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2\GWuIH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNVIh\|ryPLh?=	NH3HdWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9	MYHGeY5kfGmxbjDhd5NigQ>?		M4jJXlEhcHJ?	MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[Yxtey2mZYLpeoVlKEircz30ZYdo\WRiRlzUN{BKXERibYX0ZY51KCh3NkSgeI8hQTl\|IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IIXzbY5oKHCxbImgLFQ7OSCJbIWsJHR6eiliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliQVTQMWdtdyCtaX7hd4Uh[XO\|YYmsJGlEPTBiPTCwMlAyPjhizszNMi=>	NHnSXG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	NV7xdJV4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHzUdnk4OiCqcoO=	NU[xe\|c1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQh[0uLVD30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOTdizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	M3LUfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXu3NkBpenN?	NWTxbWVPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhS1OIMWKteJJidnOob4Lt[YQhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODJ2IN88UU4>	NHvHN4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	Mm\1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1rRcVczKGi{cx?=	NGfZflZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEMWQ5OzW\IH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNlgh\|ryPLh?=	MkfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9	MXrGeY5kfGmxbjDhd5NigQ>?		M1X4NFEhcHJ?	NID6b3NKdmirYnn0bY9vKG:oIHj1cYFvKEiONkCgZ4VtdHNvZHXybZZm\CCKaYOteIFo\2WmIF\MWFMhMDV4NDD0c{A6QTNicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcocheG:ueTCoOFoyKEeudTygWJlzMSCjczDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCDRGCtS4xwKGurbnHz[UBie3OjeTygTWM2OCB;IECuNFMxPCEQvF2u	Mo\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NHjNZ3JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUe3NkBpenN?	MlXLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2USCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMEW2JO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NGLs[pBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUHrc4REPzJiaILz	NFPKe3ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBFTFJ{LYTyZY5{\m:{bXXkJI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlEyKM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4\WS\|czKGi{cx?=	M2LFb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJGRFWjFvdILhcpNnd3KvZXSgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNVIh\|ryPLh?=	NHeyblI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
CMK	MmiwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWO3NkBpenN?	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOPSzDj[YxteyCneIDy[ZN{cW6pIF\MWFMhc2mwYYPlJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4yOiEQvF2u	M3XNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3jqdFczKGi{cx?=	M3vWTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJHJGXC22cnHud4Zwem2nZDDtc5V{\SCEQV[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6xN{DPxE1w	NIXxc5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
HL60	NH3iWG5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MonzO\|IhcHK\|	NXXJT\|d3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIV5eHKnc4PpcochTkyWMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkGzJO69VS5?	M4XoSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUewOnlCPzJiaILz	NYK2ZW9ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhTkyWND30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4zPyEQvF2u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MnfsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVfvVYM4PzJiaILz	NWXURY5jSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVu2OlNSKG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5\|NzFOwG0v	NGDRbY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYe3NkBpenN?	NF\EVVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBNS0tvdILhcpNnd3KvZXSgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuOEDPxE1w	NFrWPW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
U937	M2Xud2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1fSZVczKGi{cx?=	M2HNemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDlfJBz\XO\|aX7nJGZNXDNia3nuZZNmKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOS5{IN88UU4>	M3vhfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
SKM1	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFz6PWw4OiCqcoO=	MmjERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS12xJINmdGy\|IHX4dJJme3OrbnegSmxVOyCtaX7hd4Uh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAyNjNizszNMi=>	M33TPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
NB4	NETvNJJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmezO\|IhcHK\|	NUGwZoZFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDORlQh[2WubIOg[ZhxemW\|c3nu[{BHVFR\|IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDdwMzFOwG0v	M{W2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM13	M4fv[2NmdGxiY4njcIUh[XO\|YYm=	NE\ZPWMyODBibl2=	NVvNSIlQOTJiaILz	MYHD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNU2xOOTNiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHH0JFExOCCwTTDh[pRmeiBzMjDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[E1HSUOVIHHuZYx6e2m\|	NXnvZppDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM14	M3rUOWNmdGxiY4njcIUh[XO\|YYm=	MmnkNVAxKG6P	NIDSVmIyOiCqcoO=	NITVeVdE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOV0yPMUSgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIF1KDFyMDDuUUBi\nSncjCxNkBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\C2IQVPTJIFv[Wy7c3nz	NI\pSok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM13	MoOyRZBweHSxc3nzJIF{e2G7	NGPXPZAyODBibl2=	NYLxZlVHOTJiaILz	MmnmTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPT1zNNVMh[2WubIOgZZN{\XO\|ZXSgZZMh[2ynYY\h[4Uhd2ZiUFHSVEBifCBzMECgcm0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb3Lsc5R1cW6pIH3leIhw\A>?	M1m1[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MV4-11	NXHmUoVVSXCxcITvd4l{KGG\|c3H5	MV6xNFAhdk1?	NIfBSmQ1QCCqcoO=	M1[zWmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOuZXH2ZYdmKG:oIGDBVnAh[XRiMUCwJI5OKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	NWD4dYJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM13	M1\DdWFxd3C2b4Ppd{Bie3OjeR?=	M{DqNlExOCCwTR?=	MX2xNkBpenN?	NE\oZlZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDjZZNx[XOnLUOgZZQhOTByIH7NJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	M3fmTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	NWGw[WJKSXCxcITvd4l{KGG\|c3H5	NES4dG0yODBibl2=	NX7mVphKOjRiaILz	NXPlc4djUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTRiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	MkTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MOLM14	M323e2Fxd3C2b4Ppd{Bie3OjeR?=	MXyxNFAhdk1?	NFvpT3YzPCCqcoO=	NEP4N29KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3PUG0yPCClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDjZZNx[XOnLUOgZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	NEjSc2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MV4-11	M{PpOGFxd3C2b4Ppd{Bie3OjeR?=	MVGxNFAhdk1?	M{nMclQ5KGi{cx?=	MYfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{BkdGWjdnHn[UBw\iClYYPwZZNmNTNiYYSgNVAxKG6PIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	NGTKb3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MV4-11	MX3D[YxtKGO7Y3zlJIF{e2G7	MlriNVAxKG6P	NHrOVFkyOiCqcoO=	Mn7GR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG\|ZTDheEAyODBibl2gZYZ1\XJiMUKgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQuTkGFUzDhcoFtgXOrcx?=	NEXQcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Saos-2	NGCwbIpyUFSVIHHzd4F6			NVjrTmVzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M17DU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NWfmcWt3eUiWUzDhd5NigQ>?			MmLLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	NXrhbVRjeUiWUzDhd5NigQ>?			M3y4RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	M{S1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MmLUdWhVWyCjc4PhfS=>			M3\USZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{	MnnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NY\CW2xWeUiWUzDhd5NigQ>?			NYj0TpJweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M1rC[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MnS2dWhVWyCjc4PhfS=>			M4Pj[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	M{[xZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MlHSdWhVWyCjc4PhfS=>			NYTXOo97eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NUXqU4d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NIjuTIdyUFSVIHHzd4F6			MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NVnwdnAzeUiWUzDhd5NigQ>?			NYnMTIRyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NFnuXoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NEfCW3lyUFSVIHHzd4F6			MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MlLxdWhVWyCjc4PhfS=>			NFPCdoNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MoTEdWhVWyCjc4PhfS=>			NIHnWGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	M3W4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MlTWdWhVWyCjc4PhfS=>			M1GzV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NIm5TY1yUFSVIHHzd4F6			NEXnfnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	NEnHdFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MVfxTHRUKGG\|c3H5			Ml7sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NYTsXVhweUiWUzDhd5NigQ>?			NVTrZW1oeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MoTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M2fySZFJXFNiYYPzZZk>			Mn:1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	NY\XRphmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MluwdWhVWyCjc4PhfS=>			MnjzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MOLM13	Mn:xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1;QWlczKGi{cx?=	M1Htcmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1QVE1zMzDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2GuY3XpckBCVSCmeXWtZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDHTVUxKD1iMD6wNFIh\|ryPLh?=	NUTUR\|lPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{HJVFczKGi{cx?=	MlLDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk[WylZXnuJGFOKGS7ZT3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLkCwN{DPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
BA/F3	M33YZmZ2dmO2aX;uJIF{e2G7		MnvPO\|IhcHK\|	NFPqWIpKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBk[WylZXnuJGFOKGS7ZT3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLkCwO{DPxE1w	M3XkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
Sf9	NYHySm1RTnWwY4Tpc44h[XO\|YYm=			NGXQNJVKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVN0irc{[t[pV{\WRicnXjc41jcW6jboSgbJVu[W5iRlzUN{ApWjV5MTD0c{BUQTl\|IILld4llfWW\|KTDJWGQhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJJBwdHliKFHsZUxIdHVuTInzMHR6eiliNkqyPlU7OSCqeXTyc4Jzd22rZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYT2zN3BeSVSSLDDJR\|UxKD1iMD6wNUDPxE1w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
Sf9	NGrFOoZHfW6ldHnvckBie3OjeR?=			MX7Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUM2hqezZvZoXz[YQhemWlb33ibY5idnRid3ns[EB1gXCnIHj1cYFvKE[OVEOgLHI2PzFidH:gV\|k6OyC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdicH;sfUApSWyjLFfseUxNgXNuVInyLUA3QjJ8NUqxJIh6\HKxYoLvcYll\SCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN\|UG3BWHAtKEmFNUCgQUAxNjB\|NjFOwG0v	NXz6Xm0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
Kasumi-1	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlLvO\|IhcHK\|	Ml[1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT4F{fW2rLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOjbHPlbY4hSU1iZInlMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNFY1KM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
Sf9	NYnIUnhnTnWwY4Tpc44h[XO\|YYm=			MknkTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE9JcXN4LX\1d4VlKHKnY3;tZolv[W62IHj1cYFvKE[OVEOgLHI2PzFidH:gV\|k6OyC{ZYPp[JVmeyliREizOXkhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJJBwdHliKFHsZUxIdHVuTInzMHR6eiliNkqyPlU7OSCqeXTyc4Jzd22rZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYT2zN3BeSVSSLDDJR\|UxKD1iMD6xN\|Yh\|ryPLh?=	M4jhbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
BA/F3	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2H0RlczKGi{cx?=	NWOwVYlJT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOjbHPlbY4hSU1iZInlMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygS2k2OCB;IEGuOFUzKM7:TT6=	M3nLfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	NWmwbmkyTnWwY4Tpc44h[XO\|YYm=	NV7ITVF[OC5yMTD0c{AyODBibl2=	MXWxJIhz	NXjkOWVRUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzDheEAxNjBzIITvJFExOCCwTTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	NFPucGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	M2\W[mZ2dmO2aX;uJIF{e2G7	NF;ZVpIxNjBzIITvJFExOCCwTR?=	MY[xJIhz	NETINpJKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iTVXLNU8zKHCqb4PwbI9zgWyjdHnvckBifCCVMkG3M\|IzOSCjdDCwMlAyKHSxIEGwNEBvVSCjZoTldkAyKGi{IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	NXf5Z4RZTnWwY4Tpc44h[XO\|YYm=	NGfmXZgyKG6P	NInNN4EyKGi{	MmmxTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDZOVg6NzV7MTDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XRiMTDuUUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4SgZY5idHm\|aYO=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	MUjGeY5kfGmxbjDhd5NigQ>?	M33XO\|Ehdk1?	MnP1NUBpeg>?	MV3Jcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGG2IGm4OFIhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHH0JFEhdk1iYX\0[ZIhOSCqcjDifUBqdW23bn;icI91KGGwYXz5d4l{	NGrDc4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	NHi1cFhHfW6ldHnvckBie3OjeR?=	MWKwMlAyKHSxIEGwNEBvVQ>?	NGezTokyKGi{	M2r6cWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVVFHUOUBxcG:\|cHjvdplt[XSrb36gZZQhYTZ7NDDheEAxNjBzIITvJFExOCCwTTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	Mle2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
MV4-11	NXXRdmhTTnWwY4Tpc44h[XO\|YYm=	MWSwMlAyKHSxIEGwNEBvVQ>?	M3v2b\|EhcHJ?	NEHJenlKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBifCCWMkCyM3kzODRiYYSgNE4xOSC2bzCxNFAhdk1iYX\0[ZIhOSCqcjDifUBqdW23bn;icI91KGGwYXz5d4l{	NH;IZY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	NHzmNXVHfW6ldHnvckBie3OjeR?=	NYi5UJFOOTBibXevb4c>	M{fYT\|I1KGi{cx?=	MnPvTY4hfmm4bzDpcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBqdiCqdX3hckBOXjRvMUGgZ4VtdHNieHXuc4dz[W[2ZXSgbY4h[XSqeX3pZ{BvfS:wdTDtc5V{\SCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgXVY6PCCjdDCxNEBu\y:tZzygbZAh[W[2ZYKgNlQhcHK\|IHL5JIludXWwb3Lsc5QhdWW2aH;kJJJmdGG2aY\lJJRwKGOxboTyc4w>	M2ra[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	NGe0dHRHfW6ldHnvckBie3OjeR?=	NEe4bnQxNjFidV2=	MnzqOEBpenN?	NU\3S\|h[UW6qaXLpeIlwdiCxZjDGUHQ{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQVvUJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ2N{OgdoV{cWS3ZTDheEAxNjFidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh7NEm0OEc,Ojl6OUS5OFQ9N2F-
MV4-11	MWTGeY5kfGmxbjDhd5NigQ>?	MUCwMlEhfU1?	M2e0b\|QhcHK\|	MnK4TY5pcWKrdHnvckBw\iCITGSzJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHH0JHR6ejZ7NDDy[ZNq\HWnIHH0JFAvOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NWjmVHF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVQ6PDRpPkK5PFk1QTR2PD;hQi=>
MV4-11	NEj3UWdHfW6ldHnvckBie3OjeR?=	M2LyUVAvOSC3TR?=	Ml;DOEBpenN?	MoDZTY5pcWKrdHnvckBw\iCITGSzJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNMT:yJJBpd3OyaH;yfYxifGmxbjDheEBVcHJ{MEKvWJlzOjB2IILld4llfWW\|IHH0JFAvOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M36wTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEm0PVQ1Lz5{OUi5OFk1PDxxYU6=
MV4-11	Mn\hSpVv[3Srb36gZZN{[Xl?	MmHhNE4yKHWP	NGfZdHU1KGi{cx?=	NVL2ZZpOUW6qaXLpeIlwdiCxZjDGUHQ{KHCqb4PwbI9zgWyjdHnvckBifCCWeYK1PFkwPTlzIILld4llfWW\|IHnuJIh2dWGwIF3WOE0yOSClZXzsd{BifCByLkGgeW0h[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M4jjVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEm0PVQ1Lz5{OUi5OFk1PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT5 / STAT5 / β-catenin / p-AKT / AKT / p-ERK / ERK / p-S6 / S6; PubMed: 28625976 Cancer Res Western blot analysis of AC220 treated MV4-11 cells. Cells were starved for overnight and treated with AC220 at indicated concentrations. Cells were harvested after 2 hours treatment and lysed. Then western blots analysis was performed. The quantification of bands are shown below the gel. phospho-FLT3 / FLT3; PubMed: 22875611 Haematologica (B) The same cells were also harvested for Western blot analysis after treatment for 90 min with different concentrations of AC220. The phosphorylation of the different FLT3 proteins was determined using a phospho-FLT3 antibody.	28625976 22875611
Immunofluorescence	WGA / FLT3 ; PubMed: 28895560 Leukemia Immunofluorescence staining of FLT3-WT, FLT3 mutants or empty vector with or without AC220 treatment in transiently transfected U2OS cells. WGA (wheat germ agglutinin). Scale bar: 25 μm.	28895560
Growth inhibition assay	Cell viability; PubMed: 23967177 PLoS One K562/ABCB1 and K562/ABCG2 cells exhibit collateral sensitivity toquizartinib. K562, K562/ABCB1 and K562/ABCG2 cells were plated in the presence of quizartinib in increasing concentrations for 96 hours and viable cells were measured using the WST-1 assay.	23967177

In vivo

Oral administration of AC220 (10 mg/kg) induces time-dependent inhibition of FLT3 autophosphorylation in the FLT3-ITD–dependent MV4-11 tumor xenograft mouse model; the inhibition being 90% at 2 hours and 40% at 24 hours. AC220 significantly extends survival in a mouse model of FLT3-ITD AML with doses as low as 1 mg/kg given orally once a day. Treatment with AC220 at 10 mg/kg for 28 days results in rapid and complete regression of tumors in all mice with no tumor regrowth during the 60-day posttreatment period. AC220 displays more significant efficacy compared to sunitinib treatment which causes tumors to shrink slowly and resume growth immediately upon discontinuation of treatment in all but one of the mice. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Inhibition of FLT3 autophosphorylation: To measure inhibition of FLT3 autophosphorylation, MV4-11 or RS4;11 cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with different concentrations of AC220 for 2 hours at 37 °C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour AC220 incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform. The concentration of AC220 that inhibits FLT3-ITD or TLT3-WT autophosphorylation by 50% represents IC50 value
Cell Research:^[1]	- Collapse Cell lines: MV4-11 and RS4;11 cells Concentrations: Dissolved in DMSO, final concentration ~20 μM Incubation Time: 72 hours Method: Cells are cultured overnight in low serum media (0.5% FBS), seeded in a 96-well plate at 40 000 cells per well and exposed to AC220 for 72 hours at 37 °C. Cell viability is measured using the Cell Titer-Blue Cell Viability Assa (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female NU/NU or severe combined immunodeficient mice implanted with MV4-11 cells Dosages: ~10 mg/kg Administration: Oral gavage (Only for Reference)

References

[1] Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.

Solubility (25°C)

In vitro	DMSO	33 mg/mL (58.85 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 15% Captisol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Quizartinib (AC220) SDF

Molecular Weight	560.67
Formula	C₂₉H₃₂N₆O₄S
CAS No.	950769-58-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04459585	Completed	Drug: Dabigatran Etexilate Mesylate\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 17 2020	Early Phase 1
NCT04459598	Completed	Drug: Efavirenz\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 8 2020	Early Phase 1
NCT04473664	Recruiting	Drug: Quizartinib	Hepatic Impairment\|Moderate Impaired Hepatic Function	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 29 2020	Phase 1
NCT02984995	Completed	Drug: Quizartinib	Leukemia Myeloid Acute	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	December 8 2016	Phase 2
NCT02675478	Completed	Drug: AC220	Relapsed AML\|Refractory AML	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	February 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it possible to alter the captisol concentration to make it more dissolvable i.e 20% or 25% captisol ?
Answer:
In 15% Captisol, the compound forms s suspension at 30mg/ml. Increasing the percentage of Captisol will not convert the mixture into solution. You can use suspension for oral gavage feeding.

Target Protein Ligand Inhibitors with Unique Features

FLT3 Inhibitor in Clinical Trial

Dovitinib (TKI-258, CHIR-258) : Phase III for Metastatic Renal Cell Carcinoma.
Newest FLT3 Inhibitor

TCS 359 : Potent FLT3 inhibitor with IC50 of 42 nM.

Choose Your Country or Region

By Signaling Pathways

By product type

Quizartinib (AC220)